New vaccine aims to train immune system against lynch syndrome cancers

NCT ID NCT05078866

Ongoing ⭐️ VACCINE ⭐️ Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a vaccine called Nous-209 in 45 people with Lynch syndrome, a genetic condition that raises the risk of colon and other cancers. The vaccine is made from man-made copies of proteins that cancer cells produce, aiming to teach the immune system to recognize and attack them. The main goals are to check the vaccine's safety and see if it triggers an immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal neoplasm Colorectal Neoplasms, Hereditary Nonpolyposis Lynch syndrome colorectal carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CARCINOMA LYNCH SYNDROME

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States
University of Puerto Rico

San Juan, 00936, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.